Feb 06, 2023 7:00am EST NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023
Feb 06, 2023 7:00am EST RaDaR® Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery
Nov 21, 2022 7:00am EST RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
